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Abstract 
Background: Anti-cholinergic agents may be used to inhibit duodenal peristalsis, but they may have adverse effects. 
Shakuyakukanzoto (Shao Yao Gan Cao Tang) has an anti-spasmodic effect and has been used before for oesoph-
agogastroduodenoscopy and colonoscopy. This randomised clinical trial aimed to evaluate the inhibitory effect of 
Shakuyakukanzoto on duodenal peristalsis, and its usefulness when administered into the duodenum just before 
endoscopic retrograde cholangiopancreatography (ERCP).
Methods: Participants were recruited between June 2008 and December 2010. All were aged ≥18 years and 
provided written informed consent. Exclusion criteria were: acute pancreatitis, a history of ischemic heart disease, pro-
static hypertrophy or glaucoma, and altered/postsurgical upper gastrointestinal anatomy. The recruited participants 
were randomly assigned to the Shakuyakukanzoto group and control group. Shakuyakukanzoto 100 mg/mL solution 
or placebo (warm water) was administered directly as a spray into the duodenum during endoscopy. Efficacy was 
evaluated by observing the extent of duodenal peristalsis and assessing the difficulty of cannulating the common bile 
duct, the required time (RT) from administration to inhibition of duodenal peristalsis and the stop duration time (DT, 
the duration for which peristalsis was inhibited). Side effects were evaluated by measuring serum potassium concen-
tration after ERCP.
Results: Of 28 participants, 15 were assigned to the Shakuyakukanzoto group and 13 to the control group. Duodenal 
peristalsis was inhibited in eight of the 10 eligible participants (80.0%) in the Shakuyakukanzoto group and none (0%) 
of the nine eligible participants in the control group (P = 0.026). In the Shakuyakukanzoto group, mean RT (±standard 
deviation) was 76.0 ± 23.9 s and DT was 11.3 ± 4.2 min. No adverse effects were observed in the Shakuyakukanzoto 
group during or after ERCP.
Conclusion: Duodenal peristalsis can be inhibited by spraying Shakuyakukanzoto solution directly into the 
duodenum.
Trial registration UMIN Clinical Trials Registry (UMIN-CTR) UMIN000011469
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Background
Endoscopic retrograde cholangiopancreatography 
(ERCP) has become increasingly important in the diag-
nosis and treatment of pancreatic and biliary diseases [1]. 
It is important to obtain a clear view, without duodenal 
peristalsis, to perform ERCP safely and effectively. Anti-
spasmodics such as hyoscine-N-butylbromide or gluca-
gon are often used to inhibit duodenal spasm [2], but 
their systemic use may cause adverse events, including 
dry mouth, urinary retention, orthostatic hypotension, 
palpitations, hyperglycaemia and anaphylaxis. Further-
more, these drugs are contraindicated in participants 
with ischaemic heart disease, prostatic hypertrophy, 
glaucoma and diabetes mellitus [3, 4].
Shakuyakukanzoto (Shao Yao Gan Cao Tang), an aque-
ous mixture of extracts of Paeoniae radix (Shakuyaku, 
Shao Yao) and Glycyrrhizae radix (Kanzo, Gan Cao), is 
reported to rapidly reduce abdominal pain and muscu-
lar cramps [5, 6], and suppress contraction of the ileum 
[7]. We have previously reported the inhibitory effect of 
Shakuyakukanzoto on duodenal peristalsis during ERCP 
[8], a finding that was later corroborated by Sakai et  al. 
[9]. This randomised clinical trial aimed to evaluate the 
inhibitory effect of Shakuyakukanzoto on duodenal peri-
stalsis and its utility when administered directly into the 
duodenum just before ERCP.
Methods
Study design
This was a prospective, randomised, placebo-controlled 
trial to investigate the effectiveness of Shakuyakukan-
zoto solution on intestinal peristalsis. A CONSORT flow 
diagram of the study protocol is presented in Fig. 1 [10]. 
The study was approved by the Ethics Committee of the 
University of Toyama, Toyama, Japan (Additional file 1), 
and informed consent was obtained from all participants 
(Additional file  2). Participants scheduled for ERCP at 
Toyama University Hospital were invited at this study 
between June 2008 and December 2010. Inclusion criteria 
were: (1) participants ≥18  years old, with (2) the capac-
ity to provide written informed consent. Exclusion criteria 
were: (1) acute active pancreatitis; (2) a history of ischemic 
heart disease, prostatic hypertrophy or glaucoma, and (3) 
altered or postsurgical upper gastrointestinal anatomy. 
Randomization was achieved by a computer-generated 
list of numbers to assign group allocation.
ERCP
Endoscopic retrograde cholangiopancreatography was 
performed by one of four trained endoscopists, each 
with at least 5 years of experience (HF, SK, JN and TA). 
Images of all procedures were recorded digitally. All par-
ticipants were administered midazolam 5  mg (Astellas 
Pharma Inc., Tokyo, Japan) intravenously before the pro-
cedure, and heart rate and peripheral oxygen saturation 
were monitored by pulse oximetry during the procedure. 
We prepared a 100  mg/mL Shakuyakukanzoto solution 
by dissolving 5.0  g Shakuyakukanzoto extract (TJ-68; 
Tsumura Co., Tokyo, Japan) in 50  mL of warm water, 
while 50 mL of warm water was used as the placebo con-
trol. Both solutions were administered at 36 °C by spray-
ing directly towards the major papilla of the duodenum 
through the endoscope. Those cases with no duodenal 
peristalsis at the major papilla were excluded from the 
study, and the study drug was not administered.
Evaluation of duodenal peristalsis
We measured duodenal peristalsis during ERCP using 
a four-grade scoring system of the degree of peristalsis 
and the difficulty of cannulation previously described 
by Niwa et al. [11]. The four scores used were as follows: 
(+0) no peristalsis of the duodenum during ERCP, can-
nulation was easy to perform; (+1) slight peristalsis of 
the duodenum, cannulation was easy to perform; (+2) 
moderate peristalsis of the duodenum, cannulation was 
difficult to perform; and (+3) severe peristalsis of the 
duodenum, cannulation could not be performed.
Efficacy and side effects of Shakuyakukanzoto solution
The primary efficacy was inhibition of duodenal peri-
stalsis, calculated as the proportion of participants scor-
ing either +0 or +1 after treatment. To further assess 
the effects of Shakuyakukanzoto solution, we reviewed 
the digital recordings of ERCP to measure the required 
time (RT) from administration of the study drug until 
peristalsis was diminished, and the duration time (DT) 
of inhibition of peristalsis (Fig. 2). As hypokalaemia has 
been reported as a side effect of Shakuyakukanzoto [12], 
we measured serum potassium concentration before and 
24 h after ERCP.
Statistical analysis
The primary outcome criterion was the efficacy rate of 
Shakuyakukanzoto compared with placebo. The sample 
size calculation for this study was based on the effective 
rate achieved in a previous trial, with the response rates 
in the Shakuyakukanzoto and control groups expected 
to be 70 and 10%, respectively. The no-peristalsis rate 
was expected to be 40% [9, 13]. The target sample size 
required to detect a difference in the response rate 
between the groups with a significance level of 5% and 
a power 90% was 13 per group, including a 40% dropout 
rate. Data are expressed as mean  ±  standard deviation 
(SD). Either Fisher’s exact test or Student’s t test were 
used to compare paired data. A P value less than 0.05 was 
considered statistically significant. All statistical analyses 
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were performed using the Statview 5.0 (Abacus Concepts 
Inc., Berkeley, CA, USA).
Results
In total, 149 ERCP procedures were performed during 
the study period, and 32 participants were enrolled into 
the study. Four were excluded due to exacerbation of 
acute pancreatitis and/or cholangitis. The remaining 28 
participants fulfilled the inclusion criteria and were ran-
domly allocated to one of the two groups: 15 participants 
to the Shakuyakukanzoto group and 13 to the placebo 
control group. Five participants in the Shakuyakukan-
zoto group and four in the control group were excluded 
as no duodenal peristalsis was evident at duodenoscopy. 
Assessed for eligibility (n=32)
Excluded  (n=4)
Not meeting inclusion criteria (n=4)
Declined to participate (n=0)
Other reasons (n=0)
Analysed  (n=10)
Excluded from analysis (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Allocated to intervention (n=15)
Received allocated intervention (n=10)
Did not receive allocated intervention (n=5)
Reason(s): No peristalsis (n=5)
Lost to follow-up  (n=0)
Discontinued intervention (n=0)
Allocated to intervention (n=13)
Received allocated intervention (n=9)
Did not receive allocated intervention (n=4)
Reason(s): No peristalsis (n=4)
Analysed  (n=9)


























Stop duration time 
(DT)
Fig. 2 Required time and duration time of study drug during ERCP. Required time (RT): from study drug administration to cessation of peristalsis. 
Stop duration time (DT): from cessation to recovery of peristalsis. Both were obtained from the digital recording made of each ERCP
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Consequently, we subjected the data of 10 and nine 
participants from the Shakuyakukanzoto and control 
groups to analysis, respectively. Participants’ demo-
graphic and clinical characteristics are summarised in 
Table 1. There was no significant difference in sex, mean 
age or indication for ERCP between the groups. Duo-
denal peristalsis was inhibited in eight of the 10 partici-
pants (80.0%) in the Shakuyakukanzoto group and none 
(0%) of the control group (P = 0.026; Table 2). Mean RT 
and DT for Shakuyakukanzoto were 76.0  ±  23.9  s and 
12.4  ±  5.0  min, respectively. There was no significant 
difference in the serum potassium concentration in the 
Shakuyakukanzoto group before or after the procedure 
(4.1 ±  0.3  mEq/L versus 4.3 ±  0.3  mEq/L, respectively, 
P = 0.192; Table 2).
Discussion
To the best of our knowledge, this is the first placebo-
controlled study that has shown that Shakuyakukanzoto 
is an effective and safe anti-spasmodic premedication for 
ERCP. In a previous observational study [9], Shakuyaku-
kanzoto acted as an anti-spasmodic agent and abol-
ished duodenal peristalsis in the majority of participants 
to whom it was administered, but this was not a ran-
domised, controlled study and the extent of suppres-
sion of peristalsis was not measured. In this study, we 
excluded participants in whom duodenal peristalsis was 
not evident at duodenoscopy, and assessed peristalsis and 
its influence on the technical difficulty of cannulating the 
common bile duct using the scoring system previously 
described by Niwa et al. [11].
Gastrointestinal peristalsis may be an impediment to 
accurate endoscopic examination. Intramuscular or intra-
venous administration of an anti-cholinergic agent such as 
hyoscine-N-butyl bromide is generally required to abol-
ish peristalsis [14]. Administration of an anti-cholinergic 
drug may, however, cause potentially serious complica-
tions, including cardiovascular events, urinary retention 
and ocular hypertension [4]. Glucagon may also be used 
to reduce peristalsis, but while it has fewer adverse effects 
on the cardiovascular system, it may induce hyperglycae-
mia [15]. Therefore, these drugs are not recommended 
for participants with cardiac disease, glaucoma, prostatic 
hyperplasia or diabetes mellitus [4, 15].
Shakuyakukanzoto has two active components. Pae-
oniflorin is a bioactive component of Paeoniae radix, 
and reportedly exhibits anti-coagulant [16], neuro-
muscular blocking [17–23], immunoregulating [24] 
and anti-hyperglycaemic effects [25]. Glycyrrhizic acid 
is a bioactive component of Glycyrrhizae radix and is 
reported to have anti-inflammatory [26] and hepatopro-
tective activity [27], and inhibit anti-platelet aggrega-
tion [28] and formation of peptic ulcers [29, 30]. These 
two components may exert synergistic effects. Although 
paeoniflorin is poorly absorbed in the gastrointestinal 
tract and has low bioavailability [31, 32], its absorption 
is significantly improved when administered orally in 
Shakuyakukanzoto solution [33].
Rather than administering standard anti-spasmodic 
drugs, or administering Shakuyakukanzoto orally, we 
sprayed Shakuyakukanzoto directly into the duodenum 
during duodenoscopy, and found that duodenal peri-
stalsis was inhibited in 80% of cases. These effects were 
likely observed because the Glycyrrhizae radix report-
edly inhibits acetylcholine-induced contraction and the 
contractile machinery of smooth muscle, while Paeoniae 
radix inhibits neurogenic contraction in the small bowel 
(the latter reportedly inhibits peristalsis in guinea pig 
ileum and in mouse jejunum and ileum) [7, 34]. Although 
paeoniflorin and glycyrrhizin may be ineffective when 
applied individually, they are recognised to block neuro-
muscular synapses when applied in combination in ani-
mal models [21].
Peppermint oil, a major constituent of which is men-
thol, also inhibits the contraction of smooth mus-
cle of the gastrointestinal tract [35–37]. Instillation 
Table 1 Participants’ demographic and  clinical character-
istics
Data are presented as number (proportion, %) or mean ± standard deviation
a  Fisher’s exact test was used to assess statistical significance
b  Student’s t test was used to assess statistical significance
Shakuyakukanzoto 
group
Control group P value
Participants 10 (52.6) 9 (47.4)
Male 7 (70.0) 6 (66.7) 1.000a
Age (years old) 69.1 71.2 0.708b
Diagnostic ERCP 7 (36.8) 3 (15.8) 0.179a
Therapeutic ERCP 3 (15.8) 6 (31.6)
Table 2 Efficacy and safety of Shakuyakukanzoto
*ND no data. The required time and stop duration time in the control group 
were not measured because inhibition of duodenal peristalsis was not achieved 
with the placebo




Ceased peristalsis 8 (80.0) 0 (0)
Required time (s) 76.0 ± 23.9 ND
Stop duration time (min) 11.3 ± 23.9 ND
Potassium concentration (mEq/L)
 Before procedure 4.1 ± 0.3 4.0 ± 0.3
 24 h after procedure 4.3 ± 0.3 4.2 ± 0.2
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of peppermint oil into the colon during colonoscopy 
reduces spasm and reduces the need for intramuscular 
or intravenous anti-spasmodic agents during endoscopic 
examination [13, 38, 39]. The mechanism of smooth 
muscle relaxation brought about by peppermint oil has 
been investigated in models using the smooth muscle of 
guinea pigs and mice.
The brown colour of Shakuyakukanzoto solution 
might affect endoscopic examination by obscuring the 
entrance to the common bile duct; however, ductal can-
nulation was possible in all cases in which Shakuyaku-
kanzoto was administered. Nevertheless, its distinctive 
colour made blinding of the study to the endoscopist 
impractical.
The intraluminal administration of a rapidly acting 
agent that directly affects smooth muscle has obvious 
advantages over the systemic administration of an anti-
cholinergic drug. In this study, we evaluated the effi-
cacy of Shakuyakukanzoto administered directly into 
the duodenum immediately before ERCP. We have also 
found that Shakuyakukanzoto sprayed directly onto the 
duodenal papilla significantly reduced serum amylase 
concentration 1  h and 1  day after ERCP [40]. Although 
we assessed only ERCP, our findings might also apply to 
other endoscopic examinations, such as upper endos-
copy, balloon endoscopy and colonoscopy.
Conclusion
Duodenal peristalsis can be inhibited by spraying 
Shakuyakukanzoto solution directly into the duodenum.
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